# Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

> **NCT00343044** · PHASE2 · COMPLETED · sponsor: **Benaroya Research Institute** · enrollment: 40 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00343044
- **Lead sponsor:** Benaroya Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2010-01
- **Final completion:** 2011-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343044, "Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00343044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*